Concordantly, 3i-1246 (FLT3>  TAF1) showed superior anti-cancer activity compared to the most potent TAF1(2) bromodomain inhibitor 3i-1248 (FLT3 < TAF1), suggesting the inability of TAF1(2) targeting to improve anti-proliferative effects in MOLM13 cells (Fig 3, S1 Fig). This evidence concerns the gene FLT3 and cancer.